All In Biotech

Free tool

FAERS Monitor: Cabenuva Kit

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 212888 or its brand name (Cabenuva Kit, Cabotegravir, Rilpivirine). Reports on generic versions are filed under their own applications.

Reports

6,543

Serious

1,293

20% of reports

Hospitalization

269

Death reported

123

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • product dose omission issue722
  • injection site pain669
  • viral load increased514
  • off label use478
  • product use in unapproved therapeutic environment459
  • virologic failure434
  • pathogen resistance323
  • pain304
  • product complaint218
  • exposure during pregnancy208
  • injection site nodule203
  • blood hiv rna increased197
  • product storage error190
  • inappropriate schedule of product administration186
  • viral mutation identified160

Reports by year received

View as table
YearReports
20191
20202
2021205
2022829
20231,276
20241,500
20251,515
20261,215

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,616 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product use in unapproved therapeutic environmentSignal4593557.93122.5773,333
viral load increasedSignal514490.3448.3217,425
blood hiv rna increasedSignal197391.7338.568,090
virologic failureSignal434282.1256.5111,533
viral mutation identifiedSignal160145.9124.821,896
pathogen resistanceSignal323118.1105.936,065
injection site noduleSignal20360.452.711,586
product complaintSignal21827.924.55,583
exposure during pregnancySignal20810.89.41,837
product dose omission issueSignal7227.97.44,402
injection site painSignal6697.06.53,494
product storage errorSignal1907.06.1971
inappropriate schedule of product administrationSignal1863.32.9302
off label use4781.81.6161
pain3041.61.468

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.